The Dual Specificity Protein Kinase CLK2 pipeline drugs market research report outlays comprehensive information on the Dual Specificity Protein Kinase CLK2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Dual Specificity Protein Kinase CLK2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Oncology, and Musculoskeletal Disorders which include the indications Solid Tumor, Endometrial Cancer, and Osteoarthritis. It also reviews key players involved in Dual Specificity Protein Kinase CLK2 targeted therapeutics development with respective active and dormant or discontinued products.
The Dual Specificity Protein Kinase CLK2 pipeline targets constitutes close to five molecules. Out of which, approximately five molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, and Discovery stages are 1, 1, 1, 1, and 1 respectively.
Dual Specificity Protein Kinase CLK2 overview
Dual-specificity protein kinase CLK2, also known as CDC-like kinase 2, is a key regulator of cellular processes, particularly in the realm of RNA splicing. Belonging to the CLK family, CLK2 is recognized for its involvement in phosphorylating serine/arginine-rich (SR) proteins. These SR proteins are pivotal in the intricate machinery of pre-mRNA splicing, where they play a central role in recognizing and processing pre-mRNA transcripts. Dysregulation of CLK2 has been associated with various pathological conditions, including cancer and neurodegenerative disorders.
For a complete picture of Dual Specificity Protein Kinase CLK2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
